24 C
Vientiane
Wednesday, April 30, 2025
spot_img
Home Blog Page 767

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Advancing into new stage of sustainable growth and global innovation

SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, participated in the 43rd Annual J.P. Morgan Healthcare Conference.

During the conference, Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent, delivered a presentation highlighting 2025 as a pivotal year for significantly business growth and concreate steps in global innovation. These efforts will further strengthen the foundation for Innovent’s vision of becoming a global premier biopharma company.

Clear path to sustainable growth


Innovent has established itself as a leading brand in oncology, consistently gaining momentum with an expanding portfolio of synergistic products. Additionally, another key growth driver, the general biomedicine segment, features a highly competitive product lineup, poised to unlock the substantial opportunities in chronic disease areas.

The company remains confident in achieving its domestic product revenue target of 20 billion RMB by 2027. Alongside rapid business growth, Innovent continues to enhance operational efficiency through effective and lean management practices, ensuring sustainable and healthy operating model.

Focus on world-class technology platforms and key therapeutic areas


Innovent Academy, the company’s innovation engine, has built a world-class technology platform, encompassing ScFv engineering, T cell engager (TCE), VHH bispecific antibodies, Topo1i ADC, dual payload ADC, and antibody peptide conjugates (APC). These platforms have consistently delivered innovative molecules, providing a driving force for the company’s long-term development.


In particular, Innovent combines its world-class antibody engineering and multiple sets of differentiated linker payload technologies to create the TOPO1i ADC technology platform (SoloTx) and dual payload ADC technology platform (DuetTx), producing a pipeline of potential best-in-class (BIC) or first-in-class (FIC) ADC candidates.


The company has so far advanced 8 ADC candidates into clinic trials, supported by efficacy and safety data from over 600 patients, with multiple ADCs receiving breakthrough therapy designation (BTD). This further validates the differentiated advantage of the company’s ADC platform technology and its strong clinical execution.


Innovent continues to focus on high-potential therapeutic areas in oncology and general biomedicine. The “PD-1+precision therapies” pipeline strengthens its leadership in oncology, while the “IO+ADC” strategy is set to transform cancer treatment. Meanwhile, its general biomedicine pipeline covers next generation treatments for autoimmune, cardiovascular and metabolic, and ophthalmic diseases, aiming to elevate treatment standards for diverse patient populations.

Embracing new opportunities in global innovation

Innovent Academy’s advancements have paved the way for a globally competitive pipeline of next generation IO and ADC candidates. The company plans to expand into innovative ADCs, bispecific (multi-specific) antibodies, and next-generation autoimmune and CVM therapies for global development.

  • IBI343 (CLDN18.2 ADC): Phase 3 multi-regional clinical trial (MRCT) has been initiated in China and Japan for gastric cancer. Pancreatic cancer MRCT clinical Phase 1 data shows positive efficacy and safety signals in Chinese patients and has started patient enrollment in the U.S. Pivotal clinical trials are anticipated in 2025, subject to PoC validation.
  • IBI363:This first-in-class PD-1/IL-2α-biased bispecific antibody has shown promising Phase 1 clinical data, obtained from hundreds of patients in IO resistant non-small cell lung cancer (NSCLC), melanoma, and IO unresponsive “cold tumor” colorectal cancer (CRC). This points to its potential as the next generation IO cornerstone drug. Innovent is following up on the Phase 1b/2 expansion cohorts of these cancer types. Pivotal clinical studies in IO-resistant advanced squamous NSCLC and IO-naïve advanced melanoma are planned to launch in China in 2025, subject to PoC data and regulatory communication. A Phase 2 clinical study is ongoing in the U.S. and will further expand into cohorts for NSCLC, CRC, and melanoma.
  • IBI3009 (DLL3 ADC): Through global licensing collaboration with Roche, Innovent aims to accelerate the development of this potentially best-in-class DLL3 ADC for small cell lung cancer patients worldwide.


2025 outlook: unlocking growth opportunities

Looking ahead in 2025, the company anticipates a year of rapid growth, driven by six new drug launches and further advancements in commercialization across oncology and general biomedicine. Key highlights include:


  • Mazdutide (GCG/GLP-1): Expected approvals for weight loss and type 2 diabetes indications in the first and second half of 2025, respectively, will provide a best-in-class GCG/GLP-1 dual agonist drug offering robust weight loss and glucose reduction, substantial liver fat reduction as well as comprehensive metabolic benefits for the vast obese, overweight and diabetes population;
  • Teprotumumab (IGF-1R): Anticipated launch as China’s first anti-IGF-1R monoclonal antibody for thyroid eye disease (TED), addressing a 60-year treatment gap.
  • Picankibart (IL-23p19): Approval anticipated by late 2025. Picankibart is the first globally to report that over 80% of subjects achieved PASI 90 (≥90% improvement in psoriasis area and severity index) within 16 weeks of treatment. It also demonstrates clear advantages, including sustained long-term efficacy, effective in patients resistant to IL-17 inhibitors, and flexibility with seasonal dosing intervals. Picankibart is poised to deliver exceptional comprehensive benefits to psoriasis patients in China.

As the company advances key cornerstone products in its pipeline, we are actively expanding the development of mazdutide, teprotumumab, and picankibart into additional indications to maximize the portfolio’s value. Building on this solid foundation, next-generation candidates are gradually entering clinical development, aiming to address global challenges related to aging and chronic disease burden. These innovations focus on extending dosing intervals, oral delivery, and novel mechanisms of action.


Looking ahead to 2025, the company plans to submit NDAs or conduct ongoing registrational trials for seven drugs, while initiating pivotal or registrational trials for seven innovative pipeline candidates, pending PoC results. Additionally, molecules with global potential and novel mechanisms of action (MoAs) will progress into PoC and first-in-human studies. These efforts solidify Innovent’s vision of “growing into a global premier biopharma company.”


Scan the QR code for presentation slides


About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

 

Ricoh named a Leader in 2024 IDC MarketScape for Worldwide Cloud Managed Print and Document Services Hardcopy

Company recognised for strengths in portfolio breadth, implementation and delivery, extended services, geographic footprint and global alignment

TOKYO, Jan. 17, 2025 /PRNewswire/ — Ricoh today announced it has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Cloud Managed Print and Document Services Hardcopy 2024 Vendor Assessment (doc #US51572924, November 2024).

A premier global marketing intelligence firm, IDC evaluated vendors who had services and solutions, including cloud-based managed print and document services, contractual print service models that target both enterprise and SMB, and delivery models including capabilities and strategies deployed by hardcopy vendors in support of direct engagements and channel-delivered print services programs.

The IDC MarketScape noted, “Ricoh continues to show leadership in driving workplace innovation across all areas of the print and document ecosystem” and “Ricoh is working across multiple office ecosystems to help customers drive digital transformation by simplifying content-driven processes through the automation of tasks” as being key differentiators contributing to the company’s position as a Leader. Additionally, the IDC MarketScape noted that “Ricoh should be considered by customers looking for globalised service delivery and consistent service quality across various geographies.”

“Ricoh’s position as a Leader in the IDC MarketScape for Cloud Managed Print and Document Services Hardcopy highlights the company’s ability to generate meaningful and innovative workplace services that continue to push the boundaries of what a print and document ecosystem can be,” said Robert Palmer, Research Vice President: Imaging, Printing, and Document Solutions, IDC. “Their strategic approach and comprehensive solutions enable businesses to streamline processes and easily adapt to the ever-evolving needs of modern workplaces.”

The IDC MarketScape identified several strengths exhibited by Ricoh supporting the company as a Leader, with the report noting the following for each:

  • Portfolio Breadth: “Ricoh looks to help customers drive digital transformation through its workflow and collaboration products, while promoting security, productivity, and sustainability.”
  • Implementation and Delivery: “Ricoh’s global sales and professional services organisation plays a pivotal role in identifying customer challenges and delivering tailored business solutions.”
  • Extended Services: “Beyond traditional MPS, Ricoh offers a comprehensive range of services to support clients in their IT needs, including IT services, onsite print services, infrastructure services, cloud and security services, workflow services, and a full range of process automation services.”
  • Geographic Footprint: “Ricoh offers an expanding pool of expertise with extensive global market coverage.”
  • Global Alignment: “Ricoh aligns its cloud services portfolio across all regions, driven by global service needs and a goal to simplify and standardise the go-to-market approach.”

“We believe being recognised as a Leader in Cloud Managed Print and Document Services Hardcopy underscores our commitment to delivering best-in-class workplace services and solutions that empower businesses to optimise workflows and achieve their digital transformation goals for our customers,” said Takahiro Irisa, Senior Corporate Officer and President of Ricoh Digital Services Business Unit, Ricoh Company, Ltd. “We believe this recognition from the IDC MarketScape validates our dedication to innovation, customer-centricity, and driving measurable results for our customers.”

A leading provider of digital workplace services and cloud-based solutions to more than 1.4 million customers worldwide, Ricoh brings technology and people together to solve challenges for organisations seeking to modernise their print infrastructures and accelerate digital transformation.

For more information and to download an excerpt copy of the report, click here (PDF).

-Ends-

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilises a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

Related Links

  • IDC MarketScape names Ricoh a Leader in Worldwide Cloud MPS Vendor Assessment

https://www.ricoh.com/info/2022/0208_1   

| About Ricoh |

Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support the digital transformation of workplaces, workspaces and optimise business performance.

Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organisational capabilities nurtured over its 85-year history. In the financial year ended March 2024, Ricoh Group had worldwide sales of 2,348 billion yen (approx. 15.5 billion USD).

It is Ricoh’s mission and vision to empower individuals to find ‘Fulfillment through Work’ by understanding and transforming how people work so we can unleash their potential and creativity to realise a sustainable future.

For further information, please visit www.ricoh.com

###

© 2025 RICOH ASIA PACIFIC PTE LTD. All rights reserved. All referenced product names are the trademarks of their respective companies.

Fiji Airways Unveils Massive Sale to Fiji, Australia, New Zealand and Beyond!

NADI, Fiji, Jan. 17, 2025 /PRNewswire/ — Fiji Airways, Fiji’s national airline, has launched incredible flight deals for American travelers looking to escape winter for a relaxing getaway or thrilling adventure.

Until February 7, 2025, Fiji Airways is offering significant savings on round-trip airfares to some of the world’s most sought-after destinations, including the pristine beaches of Fiji, the Great Barrier Reef in Cairns, the iconic landmarks of Sydney, the vibrant streets of Auckland and beyond.

Available on select travel dates, travelers can fly from Los Angeles, San Francisco, Honolulu or Dallas Fort Worth to:

  • Fiji from just USD $748 on a roundtrip Value fare
  • Australia from USD $848 on a roundtrip Value fare
  • New Zealand from USD $848 on a roundtrip Value fare
  • Tonga & Western Samoa from USD $1,298 on a roundtrip Value fare

All economy value fares include one checked bag of up to 30kg, a carry-on bag of up to 7kg, complimentary meals, beverages, and in-flight entertainment, with additional fare options available for those seeking added perks and convenience.

The sale ends February 7, 2025 and is valid for select travel dates across 2025, with limited seats available. Terms and conditions apply.

Travelers can book now on fijiairways.com or through a local travel agent to experience Fiji Airways’ award-winning hospitality from the moment they step on board.

“It’s the perfect time of year to take advantage of discounted airfares and start planning your travels for the year ahead. Whether you’re dreaming of Fiji’s beaches, Australia’s vibrant cities, or New Zealand’s stunning landscapes, these exclusive offers make it easier than ever for Americans to explore exciting destinations around the world,” said Fiji Airways CEO and Managing Director Andre Viljoen.

Fiji Airways flies directly to 26 international destinations from its hub in Nadi, Fiji and offers seamless one-stop connections for Americans to popular cities including but not limited to:

  • Australia: Sydney, Melbourne, Brisbane, Adelaide, Canberra and Cairns from 10th April 2025
  • New Zealand: Auckland, Wellington, Christchurch
  • The South Pacific: Tonga, Western Samoa

About Fiji Airways:

Fiji Airways, Fiji’s national airline, has been named SKYTRAX Best Airline in Australia and the Pacific 2024 for two consecutive years and is ranked 14th in SKYTRAX Global Top 100 Airlines.  The airline was also awarded Best Airline Staff, Best Cabin Crew, Best Economy Class and Best Business Class Onboard Catering in Australia and the Pacific at the 2024 SKYTRAX awards. Fiji Airways has also received the esteemed Five Star Major Airline Award at the 2024 APEX Official Airline Ratings™, an award the airline has been recognised with for three consecutive years.

Founded in 1951, the Fiji Airways airline group comprises Fiji Airways, Fiji’s international airline, and its wholly-owned domestic and regional subsidiary, Fiji Link. From its hubs at Nadi and Suva International Airports, Fiji Airways and Fiji Link serve 108 destinations in over 15 countries (including code-share). Destinations include Fiji, Australia, New Zealand, the US, Canada, the UK, Hong Kong (SAR China), Singapore, India, Japan, China, Samoa, Tonga, Tuvalu, Kiribati, Vanuatu, Solomon Islands and New Caledonia. The Fiji Airways Group brings in 70 percent of all visitors who fly to Fiji, employs over 2000 employees, and earns revenues of over FJD$1.7 billion (USD $770m) in 2023. Fiji Airways rebranded from Air Pacific in June 2013. Visit www.fijiairways.com for more information.

Next Wave of Leading Women in AI Identified in New Global Data Set

Zeki Data’s proprietary data and scoring system has pinpointed the precise women at the forefront of AI innovation. Over 300,000 women across 90+ countries and 250+ sectors of expertise.

LONDON, Jan. 17, 2025 /PRNewswire/ — Zeki Data, a UK-based talent data and analytics company, announced today a new data insights product, Talent Multiplier, capable of identifying the precise women at the forefront of AI innovation organizations desire to hire, fund, or invest in.

Women hold only 25 percent of AI and data roles worldwide and make up less than 30 percent of scientists globally.
Women hold only 25 percent of AI and data roles worldwide and make up less than 30 percent of scientists globally.

Zeki is the only dataset that identifies hidden, underrepresented, and undervalued women science and engineering talent globally. Only 25 percent of AI and data roles worldwide are held by women and Zeki’s proprietary dataset of 300,000+ women in AI is the only dataset of its kind in the world.

“Zeki has answered the question, “where are the women?” with the creation of Talent Multiplier and its Women in AI dataset,” observed Margaux Bergen, Zeki COO and Co-Founder. “All of society benefits when women have equal footing in the development of frontier technologies. Women will shape the next wave of AI and the organizations that actively hire, invest, and fund women AI innovators will lead the market.”

AI will accelerate scientific advancement in every field and according to McKinsey & Company increase corporate profits by potentially $4.4 trillion per year. Intelligence-driven targeting of investments in women can positively impact their level of influence in the development of the next wave of AI built on frontier AI models.

Talent Multiplier provides organizations with a first mover advantage to identify investment opportunities, accelerate innovation, and premier talent. Further Zeki insights on women in AI are available in its free report on Women in AI.

Zeki Data is a talent data and analytics company that applies counter terrorism intelligence techniques to positively identify individuals, organizations, and countries capable of the greatest AI innovation. Learn more at www.zekidata.com.

 

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).

This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4].

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, “We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix. This clinically important prostate cancer imaging modality is currently recommended in international clinical practice guidelines including European Association of Urology (EAU) and European Society for Medical Oncology (ESMO).”

PSMA-PET imaging[5] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[6] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). European guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease[7] and evaluation of BCR/biochemical persistence (BCP)[8].

About Illuccix® 

Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11   and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[9], by the Australian Therapeutic Goods Administration (TGA) [10], and by Health Canada[11].

In Europe, Illuccix, after radiolabelling with gallium-68, will be indicated for detection of PSMA-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings:

  • Primary staging of patients with high-risk PCa prior to primary curative therapy
  • Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy
  • Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

[1] Positron emission tomography.

[2] The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte).

[3] Germany serves as the Reference Member State in the Decentralised Procedure. The other 18 Concerned Member States are Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Spain, and Sweden.

[4] Regulatory approval timeframe from EEA CMSs may vary considerably.

[5] Imaging of prostate-specific membrane antigen with positron emission tomography.

[6] Computed tomography.

[7] EAU, ESMO.

[8] EAU.

[9] Telix ASX disclosure 20 December 2021.

[10] Telix ASX disclosure 2 November 2021.

[11] Telix ASX disclosure 14 October 2022.

 

WiMi Develops Binary String Polynomial Encoding for Quantum Random Access Memory (QRAM)

BEIJING, Jan. 17, 2025 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WiMi) (“WiMi” or the “Company”), a leading global Hologram Augmented Reality (“AR”) Technology provider, today announced the development of a binary string polynomial encoding for Quantum Random Access Memory (QRAM). Random Access Memory (RAM) is a crucial component in classical computing, enabling computers to quickly and randomly access stored data. In the context of quantum computing, QRAM is a type of memory that allows quantum computers to efficiently and parallelly access stored data without disrupting quantum states. QRAM is not only a core architecture for quantum data storage, but also a fundamental component for many quantum algorithms, such as the Grover search algorithm and Shor’s algorithm.

However, the process of quantum data access is far more complex than in classical computing. The nature of quantum states requires that data access preserves the superposition of the states while avoiding the introduction of measurement interference. As a result, designing an efficient QRAM architecture is highly challenging. Most existing QRAM designs are very costly in terms of computational resources (such as qubits, T gates, depth, etc.), making it difficult to implement large-scale applications on practical quantum computers.

WiMi has designed an entirely new QRAM architecture by introducing binary string polynomial encoding. In this design, Clifford+T circuits are utilized, and by optimizing the use of T gates, the efficiency of quantum circuits is significantly improved. Compared to the state-of-the-art QRAM bucket brigade architecture, this design has made significant breakthroughs in multiple key metrics.

T-depth is one of the key metrics of quantum computing performance. The smaller the depth, the shorter the time required for the computational process, which in turn helps improve the overall efficiency of quantum algorithms. In this new QRAM design, we have achieved an exponential improvement in T-depth through polynomial encoding of binary strings. Specifically, in previous state-of-the-art bucket brigade QRAM architectures, the T-depth typically grows linearly with the number of memory locations, whereas WiMi has reduced the T-depth exponentially through polynomial encoding.

T-count is also a crucial optimization goal. T gates are expensive operations in quantum computing; their implementation not only consumes time but also depletes significant resources, especially in fault-tolerant quantum computing. To keep the T-count low, WiMi has adopted an innovative gate circuit optimization strategy in its design, ensuring that the T-count does not significantly increase while reducing the T-depth. Compared to previous state-of-the-art designs, this architecture maintains an asymptotically similar T-count. This means that, while the computational depth has been significantly reduced, the number of T gates required by the circuit has not increased drastically, ensuring efficient resource utilization.

Quantum bits (qubits) are the fundamental units of quantum computing and the core resource of a quantum computer. When designing a new QRAM architecture, optimizing other performance metrics while keeping the number of qubits constant has always been a significant challenge. WiMi has achieved a substantial improvement in qubit utilization efficiency through deep optimization of circuit design. In existing state-of-the-art designs, the number of qubits typically increases proportionally with the number of memory locations. However, in WiMi’s design, the same number of qubits is maintained while optimizing other computational resources (such as T-depth and T-count), resulting in a significant overall performance improvement.

WiMi’s binary string polynomial encoding for Quantum Random Access Memory (QRAM) also introduces the concept of a quantum Look-Up Table (qLUT). A qLUT, or Quantum Read-Only Memory (QROM), differs from traditional QRAM in that it has specific functional limitations. Specifically, QROM is a read-only structure, and the content it stores is fixed when the quantum state is initialized. Every time the memory content changes, the entire quantum circuit must be recompiled.

While the functionality of qLUT is limited, it shows extremely high efficiency in certain specific application scenarios. For example, when an algorithm requires frequent lookups of fixed, preset data, a qLUT can provide rapid data access at a lower computational cost. WiMi’s qLUT, combined with QRAM, further optimizes T-depth and T-count while maintaining a low qubit count, making it an extremely efficient data query tool in complex quantum algorithms.

WiMi’s binary string polynomial encoding for Quantum Random Access Memory (QRAM) technology marks a significant leap in the performance of quantum computers. This technology not only brings deep theoretical optimizations but also provides strong practical support for various application scenarios, leading to a revolutionary improvement in the storage and access performance of quantum computers. Through significant optimizations in T-depth, T-count, and qubit count, this technology breaks through the limitations of traditional QRAM architectures, making the efficient implementation of quantum computing more feasible.

In the future, this technology is expected to demonstrate immense application potential across various fields. Particularly in quantum algorithms that require fast, large-scale data access, such as chemical molecular simulations, financial market predictions, cryptography decryption, and artificial intelligence, the optimized QRAM technology will bring new possibilities for quantum computing. Especially when combined with the quantum internet currently under development, the future quantum computing ecosystem will be more efficient, stable, and scalable. As quantum computing technology continues to advance, this QRAM design will further drive the large-scale application of quantum computers in real-world scenarios.

About WiMi Hologram Cloud

WiMi Hologram Cloud, Inc. (NASDAQ:WiMi) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.

Safe Harbor Statements

This press release contains “forward-looking statements” within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company’s strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission (“SEC”) on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services.

Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.

Concept Medical Announces First Patient Enrollment in the MAGICAL BTK IDE Trial, Launching its PAD Clinical Program in the United States

TAMPA, Fla., Jan. 17, 2025 /PRNewswire/ — Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment of the first patient in the “MAGICAL BTK” (Randomized Controlled Trial of MagicTouch PTA – Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in the Treatment of Below The Knee arterial disease) U.S. Investigational Device Exemption (IDE) pivotal trial. The first patient was enrolled by Dr. Prakash Krishnan, MD, and his team at the Icahn School of Medicine at Mount Sinai, marking a crucial milestone in the advancement of treatment options for patients suffering from peripheral artery disease (PAD) below the knee.

First patient enrollment in MAGICAL-BTK IDE Study in the United States.
First patient enrollment in MAGICAL-BTK IDE Study in the United States.

Following the recent IDE Approval by the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, this enrolment heralds the beginning of Concept Medical’s peripheral clinical trial program in the United States. With the ongoing IDE study for MagicTouch SCB in coronary artery disease, Concept Medical is now actively enrolling in two U.S. clinical trials in both coronary and peripheral interventions—an unprecedented achievement aimed at improving patient outcomes and expanding therapeutic choices.

     “The enrolment of the first patient in the MAGICAL BTK trial represents an important stride toward improving the standard of care for below-the-knee disease in patients with peripheral artery disease,” said Dr. Prakash Krishnan, MD, Icahn School of Medicine at Mount Sinai. “Sirolimus-coated balloon technology has the potential to significantly enhance limb salvage and patient quality of life. I am honored to be part of this landmark study and look forward to the meaningful clinical evidence it will generate.”

The MAGICAL BTK pivotal trial is designed to evaluate the safety and effectiveness of MagicTouch PTA Sirolimus Coated Balloon compared to standard percutaneous transluminal angioplasty (PTA) for the treatment of below-the-knee arterial disease. The primary endpoint, measured at 12 months, is primary patency, ensuring that the trial’s findings focus on meaningful clinical outcomes. This global, multi-center study is led by Prof. Sahil Parikh (Chairperson), with a distinguished panel of Principal Investigators including Dr. Eric Secemsky (Beth Israel Deaconess Hospital and Harvard Medical School), Prof. Brian DeRubertis (NY Presbyterian Weill Cornell Medical Center and Cornell University Medical College), Prof. Edward Choke (Northern Heart Hospital), and Prof. Osamu Iida (Osaka Keisatsu Hospital).

     “The initiation of the MAGICAL BTK Trial heralds a new era in the treatment of patients with chronic limb-threatening ischemia and offers hope to the millions of patients with this condition who are at risk for limb loss because of insufficient arterial circulation in their legs,” stated Prof. Sahil Parikh.

Sirolimus-coated balloon technology has already reshaped coronary and peripheral artery disease management, with MagicTouch achieving positive results in large-scale trials across Asia and Europe.. Now, with the MAGICAL BTK trial, U.S. patients have the opportunity to benefit from this breakthrough approach. Concurrently, patient enrolment from Asia will broaden the global patient cohort, offering a more comprehensive understanding of the therapy’s benefits across diverse populations.

     “At Concept Medical, our unwavering commitment to innovation and patient care drives us to push the boundaries of what is possible in vascular interventions,” said Dr. Manish Doshi (Founder & Managing Director). “The start of MAGICAL BTK further validates our dedication to bringing next-generation, evidence-based solutions to clinicians and patients worldwide. Our goal is to redefine current standards, ensuring better outcomes and improved quality of life for those affected by PAD.”

With the MAGICAL BTK trial and the MAGICAL SFA IDE trial for superficial femoral artery (SFA) treatment set to begin, Concept Medical is poised to revolutionise endovascular care. The company’s distinctive technology platform has already elevated the management of coronary artery disease, and now, by expanding its reach into peripheral interventions, Concept Medical reinforces its leading position in advancing patient-focused, drug-delivery solutions.

About Concept Medical

Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus Coated Balloons (SCBs)—the world’s first and most utilized SCB technology—well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.

For more information, please visit www.conceptmedical.com.

 

Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering

NEW YORK, Jan. 17, 2025 /PRNewswire/ — Hong Kong Pharma Digital Technology Holdings Limited (“Hong Kong Pharma” or the “Company”) (NASDAQ: HKPD), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced the closing of its initial public offering (the “Offering”) of an aggregate of 1,403,685 ordinary shares, par value $0.001 per share (the “Ordinary Shares”) at a public offering price of US$4.00 per share of which 1,000,000 Ordinary Shares were offered by the Company, and 403,685 Ordinary Shares were offered by certain selling shareholders of the Company. Hong Kong Pharma did not receive any proceeds from the sale of ordinary shares by the selling shareholders. The Company’s Ordinary Shares began trading on the Nasdaq Capital Market on January 15, 2025 under the ticker symbol “HKPD.”

The aggregate gross proceeds from the Offering were $5,614,740, before deducting underwriting discounts and other related expenses, including $4,000,000 received by the Company and $1,614,740 received by the selling shareholders of the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to 150,000 Ordinary Shares to cover over-allotments at the initial public offering price, less underwriting discounts. The Company intends to use the net proceeds for the development and upgrade of its supply chain enterprise resource planning systems; to fund the procurement of warehouse equipment to improve efficiency; to fund the expansion of its sales and marketing team to accelerate the growth of its business; and to fund general working capital and for other general corporate purposes.

The Offering was conducted on a firm commitment basis. Bancroft Capital, LLC is acting as the lead underwriter, with Eddid Securities USA Inc. acting as a co-underwriter for the Offering. Bevilacqua PLLC acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities counsel to the lead underwriter in connection with the Offering.

A registration statement on Form F-1 (File No. 333-282876) relating to the Offering, as amended, was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on December 20, 2024. The Offering was made only by means of a prospectus, copies of which may be obtained from: Bancroft Capital, LLC, by standard mail to 501 Office Center Drive, Suite 130 Fort Washington, PA 19034, by email at InvestmentBanking@bancroft4vets.com, or by telephone at (+1) 484-546-8000; or Eddid Securities USA Inc., by standard mail to 40 Wall Street, Suite 1606, New York, NY 10005, by email at ecm@eddidusa.com, or by telephone at (+1) 212-363-6888. Copies of the final prospectus filed with the SEC on January 15, 2025 and the registration statement can be accessed via the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Hong Kong Pharma Digital Technology Holdings Limited

Hong Kong Pharma Digital Technology Holdings Limited offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China.

Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers. For more information, please visit the Company’s website: www.9zt.hk

Forward-Looking Statements

All forward-looking statements, expressed or implied, in this release are based only on information currently available to us and speak only as of the date on which they are made. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this release. Except as otherwise required by applicable law, we disclaim any duty to publicly update any forward-looking statement to reflect events or circumstances after the date of this release. These statements are subject to uncertainties and risks, including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the registration statement for the Offering filed with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:
Media Contact: pr@9zt.hkhevintam@anpa.com.hk 
Investor Relations: ir@9zt.hk
Standard mail: Hong Kong Pharma Digital Technology Holdings Limited, Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong
Telephone: +852 2618-9289